NASDAQ · Health care

InMed Pharmaceuticals Inc. (INM)

It posted a net loss of $12.6M. At June 30, 2026 it held $2.2M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 9, 2026.

Watch INM in 60 seconds

Price

$15.56

+19.65% on the day · November 6, 2026

52-week range $5.75 to $23.30

Market cap

$43.6M

Key facts about InMed Pharmaceuticals Inc.

Net worth: InMed Pharmaceuticals Inc. has a market value (market cap) of $43.6M at the latest share price, and shareholders' equity of $1.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $4.9M (+7.5% year on year), with a net loss of $8.2M.
Cash flow: In fiscal 2026 operations used $8.6M of cash.
Latest report: The latest periodic report (annual report, 10-K) was filed with the SEC on September 9, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report: InMed Pharmaceuticals Inc.'s next report is expected around December 15, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What InMed Pharmaceuticals Inc. does

InMed Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INM.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	n/a	n/a	-$12.6M	-$3.12	n/a
2025	$4.9M	n/a	-$8.2M	-$8.36	n/a
2024	$4.6M	n/a	-$7.7M	-$20.14	-$7M
2023	$4.1M	-$7.9M	-$7.9M	-$64.81	-$7.4M
2022	$1.4M	-$18.6M	-$18.6M	-$661.43	-$15.6M
2021	$1.9M	-$10.2M	-$10.2M	-$756.95	-$9.8M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around December 15, 2026.

Estimated from its filing rhythm: about 97 days after its last report of September 9, 2026, its usual gap. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Latest SEC filings

What InMed Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 29, 2026
Merger registration (amended) S-4/A
September 18, 2026
Stock exchange listing notice 8-K
September 9, 2026
Merger registration (amended) S-4/A
September 9, 2026
Form 425 filing 425
September 9, 2026
Annual report 10-K · period to June 30, 2026Diluted EPS -$3.12 versus -$8.36.
August 14, 2026
Passive stake (5% or more) SCHEDULE 13G
July 22, 2026
Form 425 filing 425
July 22, 2026
Form 425 filing 425
July 22, 2026
Investor disclosure 8-K
July 20, 2026
Form 425 filing 425

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 5, 2026. Insider transactions on SEC

Insider trades

What the people running InMed Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $175.2K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$175.2K

last 90 days

Sold

last 90 days

Net bought

134,021

$175.2K

Date	Insider	What	Shares	Price	Value	Filing
October 5, 2026	ADAR1 Capital Management, LLC10% owner	Boughtindirect	18,182	$1.33	$24.2K	Form 4
October 2, 2026	ADAR1 Capital Management, LLC10% owner	Boughtindirect	8,307	$1.33	$11K	Form 4
October 1, 2026	ADAR1 Capital Management, LLC10% owner	Boughtindirect	16,431	$1.33	$21.8K	Form 4
September 16, 2026	ADAR1 Capital Management, LLC10% owner	Boughtindirect	8,340	$1.29	$10.8K	Form 4
September 15, 2026	ADAR1 Capital Management, LLC10% owner	Boughtindirect	54,256	$1.30	$70.4K	Form 4
September 14, 2026	ADAR1 Capital Management, LLC10% owner	Boughtindirect	28,505	$1.29	$36.9K	Form 4
July 16, 2026	Vivo Opportunity, LLC10% owner	Boughtindirect	19	$1.55	$29.5	Form 4
July 16, 2026	Vivo Opportunity, LLC10% owner	Boughtindirect	2	$1.55	$3.1	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns INM

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
ADAR1 Capital Management, LLC13G, passive with 1 related filers	24.1%	800,000	June 5, 2026
Vivo Opportunity Fund Holdings, L.P.13D, may seek influence with 3 related filers	21.7%	718,444	June 10, 2026
YA II PN, Ltd.13G, passive with 7 related filers	9.99%	80,372	December 18, 2024
Sabby Management, LLC13G, passive with 2 related filers	9.9%	280,138	January 20, 2026
Squadron Master Fund LP13G, passive with 3 related filers	9.8%	325,000	May 27, 2026

Latest filings below 5%: Ikarian Capital, LLC 4.2% (August 14, 2026); AdvisorShares Trust 0% (April 2, 2025); Armistice Capital, LLC 4.99% (November 14, 2024).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 1,010,040 shares in total, about $15.7M at the last price.

Holder	Shares	As of
ADAR1 Capital Management, LLC10% owner	935,021935,021 held indirectly	October 5, 2026
Vivo Opportunity, LLC10% owner	75,01975,019 held indirectly	July 16, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about INM

What does InMed Pharmaceuticals Inc. do?

InMed Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as INM. Its shares trade on NASDAQ under the ticker INM.

What is InMed Pharmaceuticals Inc.'s net worth?

InMed Pharmaceuticals Inc. has a market value (market cap) of $43.6M at the latest share price, and shareholders' equity of $1.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is InMed Pharmaceuticals Inc. profitable?

No. In fiscal 2026 it reported a net loss of $12.6M.

When did InMed Pharmaceuticals Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on September 9, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 5, 2026.

When is InMed Pharmaceuticals Inc.'s next earnings report?

InMed Pharmaceuticals Inc.'s next report is expected around December 15, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

NSRX

Nasus Pharma Ltd

FLNA

Filana Therapeutics, Inc.

VERU

Veru Inc.

MCRB

Seres Therapeutics, Inc.

GRCE

Grace Therapeutics, Inc.

KPTI

Karyopharm Therapeutics Inc.

Compare INM with

Compare INM with any company

Follow INM

Get an email when InMed Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values InMed Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.